Mechanism of Action

Elacridar (GF120918) functions as a high-affinity competitive inhibitor of two major ATP-binding cassette (ABC) efflux transporters: P-glycoprotein (P-gp, encoded by ABCB1) and breast cancer resistance protein (BCRP, encoded by ABCG2). Both transporters are expressed on the luminal surface of intestinal epithelial cells, at the blood–brain barrier (BBB), and in many tumor cell types, where they actively export a broad spectrum of structurally diverse compounds, limiting intracellular drug accumulation.

By binding to the transporter substrate-binding domain and blocking ATPase-dependent efflux, Elacridar prevents the active export of co-administered substrates. Because Elacridar simultaneously inhibits both P-gp and BCRP, it is particularly valuable in settings where both transporters contribute to limiting drug exposure — a common scenario at the BBB and in multidrug-resistant (MDR) tumors.

Research Applications

1. Multidrug Resistance (MDR) Reversal: Elacridar is routinely employed in cancer biology research to sensitize MDR cell lines overexpressing P-gp or BCRP to cytotoxic agents. Co-treatment with Elacridar allows researchers to quantify the contribution of each transporter to drug resistance, helping guide the rational design of combination therapies.

2. CNS Drug Penetration Studies: At the blood–brain barrier, P-gp and BCRP cooperate to restrict CNS entry of many therapeutic candidates, including tyrosine kinase inhibitors and antiviral agents. Administering Elacridar in preclinical rodent models increases brain-to-plasma ratios of substrate drugs, providing critical pharmacokinetic data for BBB permeability assessment.

3. In Vitro Transporter Assays: Elacridar serves as a reference inhibitor in bidirectional transport assays using monolayer cell systems such as Caco-2, MDCK-MDR1, and MDCK-BCRP. Including Elacridar controls enables researchers to confirm transporter-mediated efflux and calculate net efflux ratios according to regulatory guidance (e.g., FDA, EMA drug interaction guidelines).

4. Tool Compound for Pharmacokinetic Studies: Elacridar is used to delineate the roles of intestinal efflux transporters in limiting oral bioavailability of investigational compounds, aiding ADME profiling in drug discovery pipelines.

Preparation and Handling Protocol

Stock Solution Preparation: Dissolve Elacridar in dimethyl sulfoxide (DMSO) to prepare a concentrated stock solution (typically 10–50 mM). Warm the vial briefly to room temperature before opening. Vortex thoroughly until complete dissolution is achieved. Confirm clarity of the solution before use.

Working Solution Preparation: Dilute the DMSO stock into the appropriate aqueous assay buffer or culture medium immediately before use. Keep the final DMSO concentration ≤0.1% (v/v) in cell-based assays to avoid solvent-related cytotoxicity. If precipitation is observed upon aqueous dilution, consider using a co-solvent such as PEG400 or hydroxypropyl-β-cyclodextrin for in vivo formulations.

Concentration Range: Typical in vitro inhibitory concentrations range from 0.1 to 2 µM, depending on transporter expression level and assay format. Pilot dose-response experiments are recommended to establish the optimal inhibitory concentration for each specific system.

Aliquoting and Storage: Prepare single-use aliquots to avoid repeated freeze–thaw cycles. Store at -20 °C in a tightly sealed, desiccated container, protected from light. Dissolved aliquots in DMSO are stable for up to 12 months under recommended conditions.

Vehicle Controls: Always include a DMSO vehicle control at the equivalent solvent concentration used in experimental wells to account for any solvent effects on transporter activity or cell viability.

Experimental Considerations and Troubleshooting

Selectivity Confirmation: While Elacridar is highly selective for P-gp and BCRP relative to many other transporters, researchers should be aware that at higher concentrations it may exhibit off-target effects. Always use the lowest effective concentration and confirm target engagement with appropriate positive controls.

Cell Line Selection: Use validated transporter-overexpressing cell lines (e.g., MDCK-MDR1 for P-gp, MDCK-BCRP for BCRP) alongside parental cell lines as controls. Verify transporter expression levels by qPCR or western blot prior to assay initiation.

Efflux Ratio Calculation: In bidirectional permeability assays, calculate the efflux ratio (ER) as P_app(B→A) / P_app(A→B). An ER >2 typically indicates significant efflux. Inhibition by Elacridar should reduce ER to near 1.0 if P-gp/BCRP-mediated efflux is the dominant mechanism.

In Vivo Dosing: For rodent studies, Elacridar is commonly formulated in vehicles such as PEG400/water mixtures or cyclodextrin solutions. Dose and route of administration should be optimized for each study. Consult published literature and institutional guidelines for specific formulation details, as parameters vary by study design.

Regulatory Context: When using Elacridar as a reference inhibitor in drug interaction studies intended to support regulatory submissions, follow current FDA and EMA guidance documents on transporter-mediated drug interactions.